AINDEX
Markets

ADARx Pharmaceuticals, Inc. (ADRX)

ADRXNASDAQ-GSBiotechnology: Pharmaceutical Preparations

$14.00

-0.2000 (-1.41%) today

Closed, Nov 16, 4:00 PM ET

-1.41% 1D
Market cap
$1.56bn
P/E
–
EPS, last 4 quarters
–
Dividend yield
–
Day range
–
52-week range
$12.50 to $23.21
Average volume
–
Previous close
$14.20

Analysts

4 covering

Buy4 buy, 0 hold, 0 sell

Targets a year out average $35.00, +150.0% from here

$32.00now $14.00$38.00

Earnings

next estimate $-0.3800

Next report

Sep 2026

-335.0%

estimate reported, and the surprise

News

3 latest

The company

ADARx Pharmaceuticals, Inc. is a late-clinical stage biotechnology company focused on developing next-generation RNA therapeutics designed to treat a broad spectrum of diseases. The Company is focused on advancing and expanding its pipeline of highly potent, selective and durable small interfering RNA ('siRNA') therapeutic candidates, including three clinical-stage programs and two advanced preclinical programs. ADARx's three hepatic-targeted programs are agazisiran, onvuzosiran and ADX-626, and its two extrahepatic-targeted programs are ADX-077 and ADX-199. Beyond its named programs, ADARx plans to continue to leverage its proprietary technologies to strategically expand its pipeline of next-generation siRNA therapeutics. ADARx's goal is to control the expression of specific disease drivers with highly selective RNA targeted therapies, delivering life-changing treatments for patients with urgent unmet medical needs.

Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ-GS
Region
North America

Often looked at with it

Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.